Skip to content
HowShorted

Sarepta Therapeutics, Inc. short interest in 2019

In 2019, Sarepta Therapeutics, Inc.'s disclosed short interest ran from 14.25% of shares outstanding on 15 Jan 2019 to 15.98% on 31 Dec 2019, a change of +1.73 percentage points. The year's high was 20.98% on 15 Oct 2019 and its low 13.21% on 15 May 2019, averaging 16.56% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.52 days on 31 Oct 2019. Full history: Sarepta Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Sarepta Therapeutics, Inc. in 2019

2019 in figures

Start of year
14.25% (15 Jan 2019)
End of year
15.98% (31 Dec 2019)
Change
+1.73 pp
High
20.98% (15 Oct 2019)
Low
13.21% (15 May 2019)
Average
16.56%
Highest days to cover
19.52 (31 Oct 2019)
SEC filings marked
6

Every report in 2019

Sarepta Therapeutics, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201914.25%6.83results (8-K)
31 Jan 201913.48%10.12
15 Feb 201913.42%7.29
28 Feb 201913.82%5.79results (8-K), 10-K filed
15 Mar 201915.88%5.95
29 Mar 201915.69%6.91
15 Apr 201914.71%10.58
30 Apr 201915.28%8.53
15 May 201913.21%9.7510-Q filed
31 May 201913.73%13.90
14 Jun 201913.93%14.51
28 Jun 201915.87%5.93
15 Jul 201917.35%9.11
31 Jul 201916.91%15.05
15 Aug 201918.28%7.9310-Q filed
30 Aug 201918.19%4.56
13 Sep 201918.91%9.42
30 Sep 201919.49%10.10
15 Oct 201920.98%8.48
31 Oct 201920.87%19.52
15 Nov 201919.29%9.0310-Q filed
29 Nov 201919.69%13.15
13 Dec 201918.24%13.58
31 Dec 201915.98%9.23

See also: Sarepta Therapeutics, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.